UNC13A Splice Correction Reverses TDP-43 Induced Synaptic Loss

Nuclear depletion of TDP-43 triggers widespread cryptic splicing defects and a substantial breakdown in synaptic communication while neurons remain structurally intact, [url=https://kclpure.kcl.ac.uk/portal/en/publications/unc13a-splice-correction-rescues-synaptic-dysfunction-induced-by-/]King’s College London reported[/url].

This pre-degenerative state affects spontaneous and evoked synaptic vesicle release across human cortical and spinal motor neurons. Researchers at University College London, King’s College London, and the Leibniz-Forschungsinstitut für Molekulare Pharmakologie in Berlin documented the physiological mechanics behind these functional deficits in findings published in Nature.

TDP-43 pathology characterizes the vast majority of amyotrophic lateral sclerosis cases and a large proportion of frontotemporal dementia patients. Loss of nuclear TDP-43 disrupts normal transcript processing, leading to aberrant inclusion of cryptic exons in various target genes. Among these targets, UNC13A experiences major splicing alterations linked directly to genetic risk variants for both neurodegenerative conditions.

“TDP-43 loss induces a pre-degenerative state where neurons remain structurally intact but suffer a substantial breakdown in synaptic communication,” said Matthew J. Keuss, describing the physiological consequences to Nature.

Genetic Correction of UNC13A Cryptic Splicing

Targeted genetic repair of a single cryptic splicing event in UNC13A reverses the synaptic transmission deficits induced by TDP-43 depletion. Investigators developed splice-switching antisense oligonucleotides designed to correct the aberrant splicing of UNC13A transcripts in human neurons. This intervention successfully restores release probability at individual synapses, single-vesicle release properties, and broader neuronal network synchrony.

Laboratory tests using human induced pluripotent stem cell-derived motor neurons demonstrated that antisense oligonucleotide treatment rescues the electrophysiological impairments tied to TDP-43 loss. Similar rescue effects emerged in humanized mouse models treated via intracerebroventricular administration, confirming the in vivo relevance of the therapeutic strategy.

“Together, this establishes UNC13A splice correction as a mechanistically defined and genetically validated therapeutic strategy relevant to ~97% of ALS and ~50% of FTD patients with TDP-43 pathology,” King’s College London reported.

• How quickly do antisense oligonucleotides restore synaptic function after administration in progressive neurodegenerative models?

“The author list was too long so I only included the first co-authors (Keuss, Harley, Ryadnov and Jackson) and last two corresponding authors (Burrone and Fratta),” King’s College London reported in publication metadata released on October 6, 2026.